|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||36.00 - 38.35|
|52 Week Range||24.21 - 38.35|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.33|
The study is designed to assess the safety, tolerability, and preliminary clinical activity of TPX-0022 at escalating doses in patients with advanced or metastatic solid tumors harboring genetic alterations in MET. TPX-0022 has been designed to target MET-driven tumor cells, and also modulate the tumor microenvironment by inhibition of CSF1R. “The clearance of our IND for TPX-0022 is another important milestone toward our goal to bring a new class of precision therapies to patients,” said Athena Countouriotis, M.D., president and chief executive officer.
Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs that address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in a question and answer session at the UBS Global Healthcare Conference on May 21 in New York. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.
Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the appointment of Patrick Machado, J.D. to its board of directors. Mr. Machado brings more than 20 years of biotech management and board experience, including as co-founder and chief business and financial officer of Medivation, Inc. “Pat has built a strong reputation in the biotech and broader business community for the tremendous value he has added at multiple companies throughout his career,” said Athena Countouriotis, M.D, president and chief executive officer.
Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, and Almac Diagnostic Services, a global stratified medicine company, today announced approval by the U.S. Food and Drug Administration (FDA) of an investigational device exemption (IDE) for the diagnostic assay that will be used in Turning Point’s registrational phase 2 clinical study. The next-generation sequencing (NGS) assay is intended for use in identifying patients with ROS1, NTRK1-3 and ALK gene fusions in advanced solid tumors. Clinical investigators will use the diagnostic test to determine molecular eligibility for enrollment into Turning Point’s registrational Phase 2 portion of the global TRIDENT-1 clinical study.
President & CEO of Turning Point Therapeutics Inc (NASDAQ:TPTX) Athena Countouriotis bought 12,000 shares of TPTX on 04/22/2019 at an average price of $18 a share.
SAN DIEGO, April 22, 2019 -- Turning Point Therapeutics, Inc. (Nasdaq:TPTX), a clinical-stage precision oncology company designing and developing novel drugs to address.
When Turning Point Therapeutics hits the markets Wednesday, it wants to pivot your portfolio toward the rich field of oncology. The IPO Turning Point has priced 9.25 million shares at $18 per share on ...
Turning Point Therapeutics, Inc. (TPTX), a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, today announced the pricing of its initial public offering of 9,250,000 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Turning Point Therapeutics from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $166.5 million. The shares are expected to begin trading on the Nasdaq Global Market on April 17, 2019 under the symbol "TPTX".
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Brainsway Ltd (BWAY) will issue 2.5 million shares at $11.94 Wednesday ...